IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Study Identifier
IMGN0301
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female & Male
Age
18+ years
Protocol Summary
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Study Locations
Location
Status
Location
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Status
Not applicable
Location
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Status
Not applicable
Location
Ohio State University
Columbus, Ohio, United States, 43210
Status
Not applicable
Location
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Status
Not applicable
Location
CTRC at UTHSCSA
San Antonio, Texas, United States, 78229
Status
Not applicable
Location
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Status
Not applicable
Showing {first} - {last} of {total} Results